Achieving Highest Complete Remission Rate of Any Lupus study

- Low dose voclosporin achieves CR rate of 49.4% at 48 weeks (p<.001)

- AURORA Phase III trial with low dose voclosporin on track to commence in Q2 2017

ir.auriniapharma.com/press-releases/detail/73

seekingalpha.com/article/4051484-aurinia-successful-48-week-phase-2b-trial-results-even-better-expected